http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2754452-C2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 |
filingDate | 2017-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43533a25dcf418b23840e0e526b771ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fb95e59265bc9ee5d7f8e1e711afd59 |
publicationDate | 2021-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2754452-C2 |
titleOfInvention | Combination therapy with notch and pi3k/mtor inhibitors for use in treatment of cancer |
abstract | FIELD: medicine; pharmaceutics.SUBSTANCE: group of inventions relates to the treatment of ovarian cancer using 4,4,4-trifluor-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or its pharmaceutically acceptable salt or hydrate (compound A) and 8-[5 -(1-hydroxy-1-methylethyl)pyridine-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinoline-2-one or its pharmaceutically acceptable salt (compound B). Compound A or its pharmaceutically acceptable salt or hydrate are used in an amount from 2.5 mg to 75 mg. Compound B or its pharmaceutically acceptable salt is used in an amount from 75 mg to 250 mg. Compound A and compound B can be used by simultaneous, separate or sequential administration, and can be composed for oral administration.EFFECT: combinations of compound A and compound B inhibit tumor growth, demonstrating enhanced efficiency and/or reduced toxicity.35 cl, 3 tbl, 1 ex |
priorityDate | 2016-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 328.